What Oncobit does

Oncobit AG is a Swiss precision oncology company that develops digital PCR-based liquid biopsy tests and accompanying cloud-based analysis software for non-invasive cancer monitoring. Founded as a spin-off from the University of Zurich and ETH Zurich, the company is headquartered in Schlieren, Switzerland and operates with a small core team of approximately 10-15 employees including co-founders, scientists, data scientists, and software developers.

The company's product portfolio centers on the Oncobit PM (Personalized Monitoring) platform, which detects circulating tumor DNA (ctDNA) from patient blood samples to monitor cancer progression and treatment response. Core products include a CE-IVDR marked digital PCR assay panel covering five melanoma markers (BRAF V600, NRAS Q61, GNAQ Q209, GNA11 Q209), the CE-marked Oncobit PM Analyzer software accessed via the Oncobit Portal, and Oncular, a uveal melanoma monitoring solution launched in the US market in 2026 through laboratory partner TrilliumBiO. All assays are designed to run on Bio-Rad QX200/QX600 digital PCR infrastructure, with sub-24-hour turnaround times.

Oncobit generates revenue through a combination of one-time assay sales to clinical laboratories and hospitals, recurring software platform access fees via the Oncobit Portal, and transaction-based laboratory services through TrilliumBiO in the US. Distribution is handled through direct enterprise sales and channel partnerships, notably Kempf und Pfaltz in Switzerland and TrilliumBiO in the US. The company targets three primary customer segments: pharmaceutical companies (for clinical trial monitoring and companion diagnostics), clinical laboratories (validated CE-IVDR assays), and hospitals and oncology clinics (treatment decision support). The company first generated revenue in Europe in 2024 and expanded into the US market via the TrilliumBiO partnership in 2026.

Name

Oncobit

Legal name

oncobit AG

Website

https://oncobit.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Oncobit AG is a Swiss precision oncology company developing digital PCR-based liquid biopsy assays and cloud-based analysis software for non-invasive monitoring of cancer patients, with initial focus on melanoma and uveal melanoma for clinical laboratories, hospitals, and pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Cancer Molecular Diagnostics

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)

akta.pro secondary industries

Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Liquid biopsy diagnostics
• CtDNA monitoring assays
• Digital PCR oncology
• Cancer molecular diagnostics
• Personalized cancer monitoring

Headquarters

HQ city

Zürich

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Diagnostic Assays: Sale of cancer monitoring assay kits for melanoma and other cancer types. Tests detect specific genetic mutations using digital PCR technology from patient blood samples.
2. Software Platform Access: Oncobit Portal provides secure access to the Oncobit Analyzer software for data analysis. Revenue generated through software licensing and platform access fees.
3. Laboratory Services: Through TrilliumBiO partnership in US, Oncobit provides testing services via multi-accredited laboratory, enabling physicians to order monitoring tests without local infrastructure.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Oncobit develops and sells digital PCR-based liquid biopsy diagnostic assays combined with a CE-marked cloud analysis software (Oncobit PM Analyzer) for non-invasive cancer monitoring via circulating tumor DNA (ctDNA) detection from blood samples. The portfolio includes a five-marker melanoma panel (BRAF V600, NRAS Q61, GNAQ Q209, GNA11 Q209), an uveal melanoma monitoring solution (Oncular™), and the Oncobit PM Personalized Monitoring platform, with CE-IVDR marking for the European market and US access via TrilliumBiO.

Product overview

Oncobit offers a unified portfolio centered on the Oncobit™ PM (Personalized Monitoring) platform for precision cancer care. The platform combines liquid biopsy-based diagnostic assays (including a five-marker melanoma panel and uveal melanoma test) with cloud-based data analysis software (Oncobit PM Analyzer) accessed via the Oncobit Portal. All assays run on Bio-Rad digital PCR infrastructure and carry CE-IVDR marking for the European market, with Oncular™ representing the US market offering for uveal melanoma monitoring.

Differentiator

Problem solved

Functional benefit

Brands

• Oncular™: Uveal melanoma monitoring solution launched in partnership with TrilliumBiO for the US market, enabling real-time quantitative assessment of circulating tumor DNA (ctDNA) from a simple blood draw.
• Oncobit™ PM

Products and services

• Oncobit™ PM Platform Cloud-based personalized monitoring platform for cancer care that analyzes circulating tumor DNA (ctDNA) from liquid biopsy blood samples. The platform provides molecular insights for precise cancer monitoring and therapy optimization using digital PCR technology, scalable across multiple cancer types.
• Oncobit™ PM Assays (Melanoma Panel) Digital PCR-based diagnostic assays for detecting and quantifying five critical melanoma cancer markers including BRAF V600 (V600D, V600E, V600E2, V600K, V600R), NRAS Q61 (Q61K, Q61L, Q61R), GNAQ Q209 (Q209L, Q209P), and GNA11 Q209 mutations. CE-IVDR marked, runs on Bio-Rad QX200/QX600 platforms with <24-hour turnaround time.
• Oncobit PM Analyzer CE-marked proprietary cloud-based software designed to analyze data generated by Oncobit PM Assays. Accessed via the secure Oncobit Portal, providing standardized ctDNA data processing and reporting for clinical consistency.
• Oncular™ Uveal melanoma monitoring solution providing real-time quantitative assessment of circulating tumor DNA (ctDNA) from a simple blood draw. Made available in the US market through TrilliumBiO's multi-accredited laboratory partnership.

Quantifiable outcome

• <24 hour turnaround time for ctDNA analysis
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• TrilliumBiOcoreChannel Partner/ Reseller/ Distributor · 9 December 2025Strategic partnership to bring Oncobit's uveal melanoma monitoring solution (Oncular) to the United States. TrilliumBiO provides multi-accredited laboratory services for nationwide test availability. Collaboration integrates Oncobit's Personalized Monitoring platform with TrilliumBiO's laboratory infrastructure.
• ID SolutionscoreStrategic or Co-development Partner · 1 December 2025Strategic partnership combining ID Solutions' highly sensitive digital PCR biomarker detection technology with Oncobit's monitoring assays and analytical software. Aims to accelerate cancer diagnosis and enable more precise, real-time treatment monitoring in compliance with IVDR requirements.
• Kempf und PfaltzcoreChannel Partner/ Reseller/ Distributor · 1 September 2025Swiss laboratory distributor for Oncobit PM assays. Customers in Switzerland can place orders through Kempf und Pfaltz for product distribution.
• EADO-EUMelaRegminorStrategic or Co-development Partner · 1 January 2025Joint ctDNA project integrating circulating tumor DNA into routine melanoma follow-up. Evaluates clinical utility of Oncobit's CE-IVDR marked digital PCR solution to detect relapse and complement established monitoring approaches.
• University Hospital Zurich / ETH ZurichcoreStrategic or Co-development Partner · 1 February 2024Oncobit is a HealthTech spin-off from University of Zurich. Founders are physicians and scientists from University Hospital Zurich and ETH Zurich. Ongoing research partnerships with clinical experts.

Scale indicators4 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Natera: Natera is a publicly traded molecular diagnostics company with Signatera, a leading personalized ctDNA-based MRD/monitoring test for solid tumors. Comparable in target market (oncology monitoring) and business model (tumor-informed liquid biopsy), but with a much broader assay menu and substantially greater commercial scale than Oncobit.
• Guardant Health: Guardant Health offers Guardant360, one of the most widely used liquid biopsy comprehensive genomic profiling tests for advanced cancer, along with Guardant Reveal for MRD. Direct overlap in ctDNA-based oncology testing and biomarker monitoring, though Guardant operates at far greater scale using NGS rather than digital PCR.
• Foundation Medicine (Roche): Foundation Medicine is a leading provider of comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx) for solid tumors. Overlaps with Oncobit in oncology molecular diagnostics and biopharma companion diagnostics; Oncobit's chairman Bram Goorden previously served as President of International Business at Foundation Medicine.
• Exact Sciences: Exact Sciences, known for Cologuard and Oncotype DX, has been expanding into liquid biopsy-based MRD/monitoring through its Cologuard Plus and Precision Oncology portfolio. Comparable in oncology monitoring business model and B2B sales to clinicians and biopharma, though operating at much greater scale across multiple cancer types.
• Roche Diagnostics: Roche Diagnostics is a global leader in in-vitro diagnostics, including the cobas digital PCR platform and cell-free DNA-based oncology assays. Overlaps with Oncobit in molecular oncology diagnostics and IVD commercialization; board member Dr. Daniel Schoener previously held corporate leadership at Roche Diagnostics.
• NeoGenomics: NeoGenomics provides oncology-focused clinical laboratory services including liquid biopsy assays for therapy selection and disease monitoring. Overlaps with Oncobit in offering ctDNA-based tests to oncologists and biopharma clients, but operates a much broader multi-modality testing menu.

Direct peers

• Sysmex Inostics: Sysmex Inostics specializes in highly sensitive digital PCR-based liquid biopsy testing for oncology, including the SafeSEQ and OncoBEAM platforms for ctDNA detection in melanoma and other solid tumors. Direct competitor in digital PCR-based oncology monitoring, with established biopharma and clinical laboratory customers.
• Inivata (NeoGenomics): Inivata developed RaDaR, a tumor-informed personalized ctDNA MRD assay using digital PCR technology. Directly comparable to Oncobit's PM platform in technology (digital PCR-based ctDNA), use case (personalized cancer monitoring/MRD), and target customer (oncologists, biopharma). Now part of NeoGenomics.

Others

• Bio-Rad Laboratories: Bio-Rad manufactures the QX200 and QX600 digital PCR systems on which Oncobit's PM Assays run. Comparable as enabling infrastructure for dPCR-based oncology testing; Bio-Rad also offers ddPCR reagents and certain assay kits for cell-free DNA research, partially overlapping with Oncobit's offering as a supplier/ecosystem partner.

Emerging players

• ID Solutions: ID Solutions develops highly sensitive digital PCR-based biomarker detection technology and is a strategic partner and investor in Oncobit. Comparable in dPCR technology focus and oncology applications, and now commercially aligned with Oncobit for IVDR-compliant precision oncology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncobit